ESMO Targeted Anticancer Therapies Congress 2026
Añadir al calendario
- Tipo de evento
- Congreso
- Fecha
- 16 de marzo de 2026, 07:30 – 18 de marzo de 2026, 14:30
- Lugar del evento
- Paris, Francia
- Dirigido a
- Investigadores clinicos de Fase I, desarrolladores precoces de farmacos, nuevas terapias y nuevos agentes
- Organizado por
- European Society for Medical Oncology
- tat@esmo.org
- Coordinadores científicos
- Scientific Co-Chairs:- Elena Garralda, Barcelona, Spain- Carlos Gomez-Roca, Toulouse, France- Cristian Massacesi, New York, United States of America
- Comité científico
- Scientific Committee:- Giovanni Abbadessa, Weston, United States of America- Udai Banerji, Sutton, United Kingdom- Carolyn Britten, San Mateo, United States of America- Jeremie Calais, Los Angeles, United States of America- Giuseppe Curigliano, Milan, Italy- Marco Donia, Herlev, Denmark- Cristina Duran, Cambridge, United Kingdom- Iker Huerga, Chicago, United States of America- Theresa Kolben, Leverkusen, Germany- Christophe Massard, Villejuif, France- Funda Meric-Bernstam, Houston, United States of America- Jordi Rodon, Houston, United States of America- Victoria Sanchez Perez, Sutton, United Kingdom- Lillian Siu, Toronto, Canada- Neeltje Steeghs, Amsterdam, Netherlands- Iain Tan, Singapore- Jean-Philippe Vert, Paris, France
Información sobre el evento
The journey of innovation in cancer treatment begins with early drug development. ESMO TAT serves as a dynamic, multi-stakeholder forum, uniting researchers, industry leaders, investors, regulators, and patient advocates under one roof to accelerate the delivery of life-changing anticancer therapies to patients. Join us in the pursuit to advance cancer treatment: we look forward to seeing you at this transformative event, to share new data, foster collaboration, and tackle challenges that will drive early clinical development forward. Innovate. Collaborate. Advance. Submit your abstract by 16 December 2025